{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:15:15Z","timestamp":1788401715581,"version":"build-2803163510"},"reference-count":53,"publisher":"American Chemical Society (ACS)","issue":"1","license":[{"start":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T00:00:00Z","timestamp":1517356800000},"content-version":"vor","delay-in-days":63,"URL":"https:\/\/pubs.acs.org\/page\/policy\/authorchoice_termsofuse.html"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>By screening a drug library comprising FDA approved compounds, we discovered a potent interaction between the antifungal agent haloprogin and the experimental organometallic drug RAPTA-T, to synergistically induce cancer cell killing. The combination of these two small molecules, even at low doses, elicited an improved therapeutic response on tumor growth over either agent alone or the current treatment used in the clinic in the highly aggressive syngeneic B16F10 melanoma tumor model, where classical cytotoxic chemotherapeutic agents show little efficacy. The combination with the repurposed chemodrug haloprogin provides the basis for a new powerful treatment option for cutaneous melanoma. Importantly, because synergistic induction of tumor cell death is achieved with low individual drug doses, and cellular targets for RAPTA-T are different from those of classical chemotherapeutic drugs, a therapeutic strategy based on this approach could avoid toxicities and potentially resistance mechanisms, and could even inhibit metastatic progression.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.7b00764","type":"journal-article","created":{"date-parts":[[2017,11,29]],"date-time":"2017-11-29T14:43:42Z","timestamp":1511966622000},"page":"116-126","source":"Crossref","is-referenced-by-count":18,"title":["Drug Repurposing Approach Identifies a Synergistic\nDrug Combination of an Antifungal Agent and an Experimental Organometallic\nDrug for Melanoma Treatment"],"prefix":"10.1021","volume":"15","author":[{"given":"Tina","family":"Riedel","sequence":"first","affiliation":[{"name":"Swiss Federal Institute of Technology (EPFL) , , ,","place":["Lausanne, Switzerland, 1015"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Demaria","sequence":"additional","affiliation":[{"name":"University Hospital of Lausanne , , ,","place":["Lausanne, Switzerland, 1011"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Zava","sequence":"additional","affiliation":[{"name":"Swiss Federal Institute of Technology (EPFL) , , ,","place":["Lausanne, Switzerland, 1015"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Joncic","sequence":"additional","affiliation":[{"name":"University Hospital of Lausanne , , ,","place":["Lausanne, Switzerland, 1011"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Gilliet","sequence":"additional","affiliation":[{"name":"University Hospital of Lausanne , , ,","place":["Lausanne, Switzerland, 1011"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3117-3249","authenticated-orcid":true,"given":"Paul J.","family":"Dyson","sequence":"additional","affiliation":[{"name":"Swiss Federal Institute of Technology (EPFL) , , ,","place":["Lausanne, Switzerland, 1015"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2017,11,29]]},"reference":[{"issue":"1","key":"2026090221464876600_cit1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nrc1529","article-title":"Timeline: Chemotherapy\nand the War on Cancer","volume":"5","author":"Chabner","year":"2005","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"2026090221464876600_cit2","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.chembiol.2013.04.007","article-title":"DNA-Damaging Agents in Cancer Chemotherapy:\nSerendipity and Chemical Biology","volume":"20","author":"Cheung-Ong","year":"2013","journal-title":"Chem. Biol."},{"issue":"1","key":"2026090221464876600_cit3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.5455\/2319-2003.ijbcp000812","article-title":"Toxicities\nof Anticancer Drugs and Its Management","volume":"1","author":"Remesh","year":"2012","journal-title":"Int.\nJ. Basic Clin. Pharmacol."},{"issue":"4","key":"2026090221464876600_cit4","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1093\/carcin\/bgt086","article-title":"A Tale of Two Approaches:\nComplementary\nMechanisms of Cytotoxic and Targeted Therapy Resistance May Inform\nnext-Generation Cancer Treatments","volume":"34","author":"Masui","year":"2013","journal-title":"Carcinogenesis"},{"issue":"6","key":"2026090221464876600_cit5","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1056\/NEJMoa0808268","article-title":"Chemotherapy,\nBevacizumab, and Cetuximab in Metastatic Colorectal Cancer","volume":"360","author":"Tol","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"2026090221464876600_cit6","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel\nplus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"2026090221464876600_cit7","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-Based\nChemotherapy\nplus Cetuximab in Head and Neck Cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N. Engl.\nJ. Med."},{"issue":"8","key":"2026090221464876600_cit8","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1039\/C3SC53243G","article-title":"NKP-1339, the First Ruthenium-Based Anticancer Drug\non the Edge to Clinical Application","volume":"5","author":"Trondl","year":"2014","journal-title":"Chem. Sci."},{"issue":"3","key":"2026090221464876600_cit9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/BF01410134","article-title":"Antineoplastic\nActivity of Three\nRuthenium Derivatives against Chemically Induced Colorectal Carcinoma\nin Rats","volume":"118","author":"Seelig","year":"1992","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"1","key":"2026090221464876600_cit10","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0022-3565(24)38169-8","article-title":"In Vitro Cell Cycle Arrest, in Vivo\nAction on Solid Metastasizing Tumors, and Host Toxicity of the Antimetastatic\nDrug NAMI-A and Cisplatin","volume":"289","author":"Bergamo","year":"1999","journal-title":"J. Pharmacol. Exp.\nTher."},{"issue":"5","key":"2026090221464876600_cit11","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00775-010-0642-1","article-title":"Intracellular\nProtein Binding Patterns of the Anticancer Ruthenium Drugs KP1019\nand KP1339","volume":"15","author":"Heffeter","year":"2010","journal-title":"JBIC, J. Biol. Inorg. Chem."},{"issue":"6","key":"2026090221464876600_cit12","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1039\/c0mt00101e","article-title":"Cellular Uptake and Subcellular Distribution\nof Ruthenium-Based Metallodrugs under Clinical Investigation versus\nCisplatin","volume":"3","author":"Groessl","year":"2011","journal-title":"Met. Integr. Biometal Sci."},{"issue":"2","key":"2026090221464876600_cit13","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.18632\/oncotarget.13711","article-title":"A Ruthenium Anticancer Compound Interacts\nwith Histones\nand Impacts Differently on Epigenetic and Death Pathways Compared\nto Cisplatin","volume":"8","author":"Licona","year":"2016","journal-title":"Oncotarget"},{"key":"2026090221464876600_cit14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ccr.2015.06.014","article-title":"The Development\nof RAPTA Compounds for the Treatment of Tumors","volume":"306","author":"Murray","year":"2016","journal-title":"Coord. Chem. Rev."},{"issue":"12","key":"2026090221464876600_cit15","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1021\/jm050015d","article-title":"In Vitro\nand in Vivo Evaluation of Ruthenium(II)-Arene PTA Complexes","volume":"48","author":"Scolaro","year":"2005","journal-title":"J. Med. Chem."},{"key":"2026090221464876600_cit16","doi-asserted-by":"publisher","first-page":"14860","DOI":"10.1038\/ncomms14860","article-title":"Allosteric\nCross-Talk\nin Chromatin Can Mediate Drug-Drug Synergy","volume":"8","author":"Adhireksan","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"2026090221464876600_cit17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10637-014-0175-5","article-title":"Preclinical Combination\nTherapy of the Investigational Drug NAMI-A(+) with Doxorubicin for\nMammary Cancer","volume":"33","author":"Bergamo","year":"2015","journal-title":"Invest. New Drugs"},{"issue":"11","key":"2026090221464876600_cit18","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1158\/1078-0432.CCR-07-0164","article-title":"Mifepristone Inhibits Ovarian Cancer\nCell Growth in Vitro and in Vivo","volume":"13","author":"Goyeneche","year":"2007","journal-title":"Clin. Cancer\nRes."},{"key":"2026090221464876600_cit19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/1471-2407-11-207","article-title":"Antiprogestin\nMifepristone Inhibits the Growth of Cancer Cells of Reproductive and\nNon-Reproductive Origin Regardless of Progesterone Receptor Expression","volume":"11","author":"Tieszen","year":"2011","journal-title":"BMC Cancer"},{"issue":"7","key":"2026090221464876600_cit20","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1517\/17425255.4.7.973","article-title":"Thalidomide in Multiple\nMyeloma--Clinical Trials and\nAspects of Drug Metabolism and Toxicity","volume":"4","author":"Breitkreutz","year":"2008","journal-title":"Expert\nOpin. Drug Metab. Toxicol."},{"issue":"7","key":"2026090221464876600_cit21","doi-asserted-by":"publisher","first-page":"ix","DOI":"10.4172\/1948-5956.1000e108","article-title":"Drug Repurposing\nfor Cancer Therapy","volume":"4","author":"Telleria","year":"2012","journal-title":"J. Cancer Sci. Ther."},{"key":"2026090221464876600_cit22","doi-asserted-by":"publisher","first-page":"6220","DOI":"10.1038\/ncomms7220","article-title":"Quantitative High Throughput Screening\nUsing a Primary Human Three-Dimensional Organotypic Culture Predicts\nin Vivo Efficacy","volume":"6","author":"Kenny","year":"2015","journal-title":"Nat. Commun."},{"issue":"2","key":"2026090221464876600_cit23","doi-asserted-by":"publisher","first-page":"e0171052","DOI":"10.1371\/journal.pone.0171052","article-title":"Repositioning\nApproved Drugs for the Treatment of Problematic Cancers Using a Screening\nApproach","volume":"12","author":"Varbanov","year":"2017","journal-title":"PLoS One"},{"issue":"7607","key":"2026090221464876600_cit24","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/534314a","article-title":"Can You Teach\nOld Drugs New Tricks?","volume":"534","author":"Nosengo","year":"2016","journal-title":"Nature"},{"issue":"2","key":"2026090221464876600_cit25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"A Simple\nStatistical Parameter for\nUse in Evaluation and Validation of High Throughput Screening Assays","volume":"4","author":"Zhang","year":"1999","journal-title":"J. Biomol. Screening"},{"issue":"13","key":"2026090221464876600_cit26","doi-asserted-by":"publisher","first-page":"9792","DOI":"10.1074\/jbc.M109.082305","article-title":"Anti-Inflammatory\nCompounds Parthenolide\nand Bay 11\u20137082 Are Direct Inhibitors of the Inflammasome","volume":"285","author":"Juliana","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"44","key":"2026090221464876600_cit27","doi-asserted-by":"publisher","first-page":"7330","DOI":"10.1038\/sj.onc.1207995","article-title":"Antitumor\nAgent Parthenolide Reverses\nResistance of Breast Cancer Cells to Tumor Necrosis Factor-Related\nApoptosis-Inducing Ligand through Sustained Activation of c-Jun N-Terminal\nKinase","volume":"23","author":"Nakshatri","year":"2004","journal-title":"Oncogene"},{"issue":"2","key":"2026090221464876600_cit28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2478\/v10042-008-0019-2","article-title":"Molecular Basis of Parthenolide-Dependent\nProapoptotic Activity in Cancer Cells","volume":"46","author":"Pajak","year":"2008","journal-title":"Folia\nHistochem. Cytobiol."},{"issue":"1","key":"2026090221464876600_cit29","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.canlet.2007.03.002","article-title":"Parthenolide Induces\nSignificant\nApoptosis and Production of Reactive Oxygen Species in High-Risk Pre-B\nLeukemia Cells","volume":"254","author":"Zunino","year":"2007","journal-title":"Cancer Lett."},{"issue":"2","key":"2026090221464876600_cit30","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.canlet.2004.03.033","article-title":"Involvement\nof Proapoptotic Bcl-2\nFamily Members in Parthenolide-Induced Mitochondrial Dysfunction and\nApoptosis","volume":"211","author":"Zhang","year":"2004","journal-title":"Cancer Lett."},{"issue":"5","key":"2026090221464876600_cit31","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1128\/am.19.5.746-750.1970","article-title":"Haloprogin: A Topical\nAntifungal Agent","volume":"19","author":"Harrison","year":"1970","journal-title":"Appl. Microbiol."},{"issue":"5","key":"2026090221464876600_cit32","doi-asserted-by":"publisher","first-page":"674","DOI":"10.2165\/00003495-199243050-00004","article-title":"Superficial Fungal\nInfections of the Skin. Diagnosis\nand Current Treatment Recommendations","volume":"43","author":"Rezabek","year":"1992","journal-title":"Drugs"},{"issue":"3","key":"2026090221464876600_cit33","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical\nBasis, Experimental Design, and Computerized Simulation of Synergism\nand Antagonism in Drug Combination Studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"2026090221464876600_cit34","doi-asserted-by":"publisher","first-page":"S21214","DOI":"10.4137\/CGM.S21214","article-title":"Current State of Animal\n(Mouse) Modeling in Melanoma Research","volume":"8s1","author":"Kuzu","year":"2015","journal-title":"Cancer\nGrowth Metastasis"},{"issue":"4","key":"2026090221464876600_cit35","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1084\/jem.178.4.1223","article-title":"Antitumor and Antimetastatic\nActivity of Interleukin 12 against Murine Tumors","volume":"178","author":"Brunda","year":"1993","journal-title":"J. Exp. Med."},{"issue":"50","key":"2026090221464876600_cit36","doi-asserted-by":"publisher","first-page":"15408","DOI":"10.1073\/pnas.1512832112","article-title":"STING Activation of Tumor Endothelial Cells Initiates\nSpontaneous and Therapeutic Antitumor Immunity","volume":"112","author":"Demaria","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"2026090221464876600_cit37","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1021\/cb600362d","article-title":"Inhibition\nof Angiogenesis by the Antifungal Drug Itraconazole","volume":"2","author":"Chong","year":"2007","journal-title":"ACS Chem. Biol."},{"issue":"5","key":"2026090221464876600_cit38","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/(SICI)1097-0215(19990301)80:5&lt;744::AID-IJC19&gt;3.0.CO;2-5","article-title":"Expression of DNA Repair Proteins\nHMSH2, HMSH6, HMLH1, O6-Methylguanine-DNA Methyltransferase and N-Methylpurine-DNA\nGlycosylase in Melanoma Cells with Acquired Drug Resistance","volume":"80","author":"Lage","year":"1999","journal-title":"Int. J. Cancer"},{"issue":"12","key":"2026090221464876600_cit39","doi-asserted-by":"publisher","first-page":"4742","DOI":"10.1039\/C4SC01255K","article-title":"In Vivo Anti-Tumor\nActivity of the Organometallic Ruthenium(II)-Arene Complex [Ru(H6-p-Cymene)Cl2(Pta)]\n(RAPTA-C) in Human Ovarian and Colorectal Carcinomas","volume":"5","author":"Weiss","year":"2014","journal-title":"Chem. Sci."},{"issue":"3","key":"2026090221464876600_cit40","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/0041-008X(72)90243-8","article-title":"Toxicologic Properties\nand Metabolic Fate of Haloprogin,\nan Antifungal Agent","volume":"22","author":"Weikel","year":"1972","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"2","key":"2026090221464876600_cit41","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s13277-013-0653-y","article-title":"The Curcumin Analog\nDM-1 Induces Apoptotic Cell Death in Melanoma","volume":"34","author":"Faia\u0303o-Flores","year":"2013","journal-title":"Tumor Biol."},{"issue":"5A","key":"2026090221464876600_cit42","first-page":"2625","article-title":"The PARP\nInhibitor, ABT-888 Potentiates Temozolomide: Correlation with Drug\nLevels and Reduction in PARP Activity in Vivo","volume":"28","author":"Palma","year":"2008","journal-title":"Anticancer Res."},{"issue":"7","key":"2026090221464876600_cit43","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/gt.2011.123","article-title":"The Combination of\nChemotherapy with HVJ-E Containing Rad51 SiRNA Elicited Diverse Anti-Tumor\nEffects and Synergistically Suppressed Melanoma","volume":"19","author":"Kiyohara","year":"2012","journal-title":"Gene Ther."},{"issue":"5","key":"2026090221464876600_cit44","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrc1613","article-title":"Immunotherapy and Chemotherapy--a Practical Partnership","volume":"5","author":"Lake","year":"2005","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"2026090221464876600_cit45","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1084\/jem.20050915","article-title":"Caspase-Dependent Immunogenicity\nof Doxorubicin-Induced Tumor Cell Death","volume":"202","author":"Casares","year":"2005","journal-title":"J.\nExp. Med."},{"issue":"2","key":"2026090221464876600_cit46","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00262-012-1388-0","article-title":"Chemoimmunotherapy: Reengineering Tumor Immunity","volume":"62","author":"Chen","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"issue":"5","key":"2026090221464876600_cit47","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nri2545","article-title":"Immunogenic and Tolerogenic\nCell Death","volume":"9","author":"Green","year":"2009","journal-title":"Nat. Rev. Immunol."},{"issue":"18","key":"2026090221464876600_cit48","doi-asserted-by":"publisher","first-page":"7102","DOI":"10.1158\/0008-5472.CAN-10-1316","article-title":"Chemotherapy-Induced\nGenotoxic Stress\nPromotes Sensitivity to Natural Killer Cell Cytotoxicity by Enabling\nMissing-Self Recognition","volume":"70","author":"Fine","year":"2010","journal-title":"Cancer Res."},{"issue":"5","key":"2026090221464876600_cit49","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1053\/sonc.2002.35238","article-title":"Metastatic Melanoma: Chemotherapy","volume":"29","author":"Bajetta","year":"2002","journal-title":"Semin. Oncol."},{"issue":"19","key":"2026090221464876600_cit50","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.3748\/wjg.v16.i19.2428","article-title":"Expression\nof Calreticulin Is Associated with Infiltration of T-Cells in Stage\nIIIB Colon Cancer","volume":"16","author":"Peng","year":"2010","journal-title":"World J. Gastroenterol."},{"issue":"5A","key":"2026090221464876600_cit51","first-page":"2939","article-title":"Increase of\nTumour Infiltrating Lymphocytes in Mice Treated with Antimetastatic\nDoses of NAMI-A","volume":"20","author":"Magnarin","year":"2000","journal-title":"Anticancer Res."},{"issue":"11","key":"2026090221464876600_cit52","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1158\/1078-0432.CCR-13-3141","article-title":"Molecular\nPathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics","volume":"20","author":"Hato","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"2026090221464876600_cit53","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1622","article-title":"Toll-like\nReceptor 4\u2013dependent Contribution of the Immune System to Anticancer\nChemotherapy and Radiotherapy","volume":"13","author":"Apetoh","year":"2007","journal-title":"Nat. Med."}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.7b00764","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/15\/1\/116\/67090925\/acs.molpharmaceut.7b00764.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/15\/1\/116\/67090925\/acs.molpharmaceut.7b00764.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T01:49:39Z","timestamp":1788400179000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/15\/1\/116\/743073\/Drug-Repurposing-Approach-Identifies-a-Synergistic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,29]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,11,29]]},"published-print":{"date-parts":[[2018,1,2]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b00764","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,29]]}}}